Finance
Roche ramps up AI computing capacity with Nvidia chip expansion
Published by Global Banking & Finance Review®
Posted on March 16, 2026
2 min readLast updated: March 16, 2026
Quick Summary
Roche has deployed 2,176 Nvidia Blackwell GPUs across US and Europe—now the largest GPU footprint in pharma—to accelerate AI-driven drug and diagnostics R&D processes.
Roche Accelerates Drug Development with Nvidia AI Chip Expansion in US & Europe
Roche Expands AI Computing Capacity to Boost Drug and Diagnostics Development
BERLIN, March 16 (Reuters) - Swiss drugmaker Roche said on Monday it had expanded its artificial intelligence computing capacity with more than 2,100 Nvidia chips to support drug and diagnostics development.
Enhanced Research and Development Operations
Roche said the additional hardware would speed up work across its research and development operations, including modelling, data analysis and clinical trial processes.
Largest GPU Footprint in the Industry
The drugmaker said it had deployed 2,176 Nvidia Blackwell graphics processing units (GPUs) across sites in the U.S. and Europe, giving it the largest GPU footprint in the industry.
Collaboration with Nvidia and AI Investment
The build-up, which began in 2023, is part of a wider collaboration with Nvidia by Roche, which has been increasing investment in AI tools as large pharmaceutical groups compete to cut development timelines and reduce costs.
Importance of Speed in Healthcare
"In healthcare, time is the most critical variable," Chief Digital and Technology Officer Wafaa Mamilli said.
AI Tools Transforming the Pharmaceutical Industry
Drugmakers have announced a slew of deals for tools to unleash the promise of artificial intelligence, seen as the biggest technological breakthrough since the internet.
Agentic AI and Productivity Gains
Agentic AI, which requires little human intervention, could increase clinical development productivity by about 35% to 45% over the next five years, consultancy McKinsey said last year.
(Reporting by Maggie Fick, Writing by Friederike Heine; Editing by Alexander Smith)
Key Takeaways
- •Roche now operates the largest GPU deployment in the pharmaceutical industry using 2,176 Nvidia Blackwell GPUs across the US and Europe to boost AI-led R&D acceleration.
- •This expansion supports modeling, data analysis, and clinical trial workflows to shorten drug development timelines and cut costs.
- •Agentic AI could enhance clinical development productivity by 35–45% over five years, underscoring the strategic value of Roche’s AI infrastructure investment.
Frequently Asked Questions about Roche ramps up AI computing capacity with Nvidia chip expansion
1How many Nvidia GPUs has Roche deployed for its AI operations?
Roche has deployed 2,176 Nvidia Blackwell GPUs across sites in the U.S. and Europe.
2What is the purpose of Roche’s investment in AI hardware?
Roche’s AI hardware expansion aims to speed up drug and diagnostics development, including modeling, data analysis, and clinical trial processes.
3When did Roche start building up its AI computing infrastructure with Nvidia chips?
Roche began the build-up of its Nvidia AI computing infrastructure in 2023.
4Why is agentic AI important in pharmaceutical development?
Agentic AI, with minimal human intervention, can increase clinical development productivity by 35% to 45% over five years, according to McKinsey.
5Which regions benefit from Roche’s expanded AI capabilities?
Roche’s expanded AI capabilities benefit its research sites in both the U.S. and Europe.
